Testing effectiveness (Phase 2)Study completedNCT00482430
What this trial is testing
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
Who this might be right for
Paranoid SchizophreniaSchizophrenia
Merck Sharp & Dohme LLC 50